fidanacogene elaparvovec

AXP000255.1 · Viral vector gene therapy

Platform
AAVRh74var vector
Targets
F9
Originator
Spark Therapeutics
Sponsor
Pfizer

Names

NameTypeSource
fidanacogene elaparvovecpreferred namecurator
Beqvezbrandfda
Durveqtixbrandcurator
PF-06838435former codecurator
SPK-9001former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus rh74 (variant capsid)
Strain
AAVRh74var
Replication
non replicating
Modifications
liver-directed expression cassette
Transgenes
F9 (R338L Padua variant)
Route
intravenous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2024-04-25approvedBeqvezAdults with moderate to severe haemophilia B on routine prophylaxissource
EMAEU2024-07-24withdrawnDurveqtixSevere and moderately severe haemophilia B; conditional authorisation withdrawn 2025-05-15 at the holder's requestsource

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05568719Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyRecruitingPhase 32022-12-282040-02-25173Hemophilia A; Hemophilia B
NCT03861273A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BActive not recruitingPhase 32019-07-292022-11-1651Hemophilia B
NCT03307980Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BTerminatedPhase 22017-06-222026-07-2321Hemophilia B
NCT02484092A Gene Therapy Study for Hemophilia BCompletedPhase 22015-11-182019-04-0815Hemophilia B

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41110511Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial.Journal of thrombosis and haemostasis : JTH2026name in title: fidanacogene elaparvovec
PMID 41734390Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.Blood advances2026cited by trial NCT03307980
PMID 42941822Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B.International journal of molecular sciences2026name in title: fidanacogene elaparvovec
PMID 40239068Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.The New England journal of medicine2025cited by trial NCT03307980
PMID 40750723Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B.Clinical pharmacokinetics2025cited by trial NCT02484092
PMID 38863155Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec.Thrombosis and haemostasis2024cited by trial NCT02484092
PMID 39321362Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.The New England journal of medicine2024cited by trial NCT03861273
PMID 29211678Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.The New England journal of medicine2017cited by trial NCT02484092

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40785174A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy.Current gene therapy2026name in abstract: fidanacogene elaparvovec
PMID 41263376Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study.Haemophilia : the official journal of the World Federation of Hemophilia2026name in title: fidanacogene elaparvovec
PMID 41381305Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.Blood reviews2026name in abstract: fidanacogene elaparvovec
PMID 41773269Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.Journal of blood medicine2026name in abstract: fidanacogene elaparvovec
PMID 42433651Overview of Patient-Reported Outcomes in Haemophilia Gene Therapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026name in abstract: SPK-9001
PMID 42676001Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: fidanacogene elaparvovec
PMID 42947409Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: fidanacogene elaparvovec
PMID 42976908Patient-Relevant Questions on Gene Therapy for Haemophilia.Hamostaseologie2026name in abstract: fidanacogene elaparvovec
PMID 42984386Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products.Haematologica2026name in abstract: fidanacogene elaparvovec
PMID 39868419Gene-ius at work: Hemophilia B treatment enters a new era.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2025name in abstract: fidanacogene elaparvovec
PMID 40156191The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: Beqvez
PMID 40488175Gene-based therapies for hemophilia.Research and practice in thrombosis and haemostasis2025name in abstract: fidanacogene elaparvovec
PMID 41229950Role of Pharmacy Professionals in Gene Therapy Based on Adeno-Associated Viruses: Treatment of Hemophilia as a Template of Care.The Canadian journal of hospital pharmacy2025name in abstract: fidanacogene elaparvovec
PMID 38472707Fidanacogene Elaparvovec: First Approval.Drugs2024name in title: fidanacogene elaparvovec
PMID 38905534Beqvez - another gene therapy for hemophilia B.The Medical letter on drugs and therapeutics2024name in title: Beqvez
PMID 33636038Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua.Journal of thrombosis and haemostasis : JTH2021name in abstract: fidanacogene elaparvovec

Notes

Recombinant AAVRh74var capsid carrying the factor IX Padua (R338L) variant for haemophilia B. Approved in the US as Beqvez (2024-04-25) and in the EU as Durveqtix (conditional, 2024-07-24), which EMA has since renamed Beqvez, so its EPAR is now at .../EPAR/beqvez; the EU authorisation was withdrawn at Pfizer's request on 2025-05-15 for commercial reasons and the product was never marketed there. The capsid is the label's AAVRh74var, not the AAV-Spark100 name used in earlier literature.

How to cite

fidanacogene elaparvovec (AXP000255.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000255.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.